Diagnostic Value of Abnormal Prothrombin for Primary Liver Cancer

Objective: To investigate the diagnostic value of abnormal serum prothrombin levels in hepatocellular carcinoma (HCC). Methods: A total of 298 patients were diagnosed with HCC at Hunan Provincial People’s Hospital between January 1, 2019, and December 31, 2024, through imaging or liver biopsy, along with 100 patients with cirrhosis, 100 patients with chronic hepatitis B virus infection, and 89 healthy controls, were included in the study. Basic demographic information, as well as levels of abnormal serum prothrombin and alpha-fetoprotein (AFP), were collected. The levels of abnormal serum prothrombin and AFP across the four groups were compared, and their diagnostic efficacy for HCC was analyzed using ROC curve analysis. Results: Abnormal prothrombin levels were significantly higher in the liver cancer group compared to the cirrhosis, hepatitis, and healthy control groups (P < 0.05). No significant differences in abnormal serum prothrombin levels were observed among the cirrhosis, hepatitis, and healthy control groups (P > 0.05). Serum AFP levels were significantly higher in the liver cancer group compared to the cirrhosis, hepatitis, and healthy control groups (P < 0.05) and were higher in the hepatitis group compared to the cirrhosis and healthy control groups (P < 0.05). However, no significant difference in AFP levels was found between the cirrhosis and healthy control groups (P > 0.05). ROC curve analysis indicated that the area under the curve (AUC) for abnormal serum prothrombin and AFP in diagnosing HCC was 0.925 (95% CI: 0.901–0.949) and 0.810 (95% CI: 0.775–0.845), respectively, with sensitivities and specificities of 84% and 75% for abnormal prothrombin and 94% and 76% for AFP. For the diagnosis of AFP-negative HCC, the AUC for abnormal serum prothrombin was 0.838 (95% CI: 0.774–0.901), with a sensitivity and specificity of 65% and 95%, respectively. Conclusion: Serum abnormal prothrombin levels are highly expressed in HCC patients and demonstrate strong diagnostic efficacy for HCC.

Authors

Institutions

Publication Details

Journal
Proceedings of Anticancer Research
Published
2024-11-25
DOI
https://doi.org/10.26689/par.v8i6.8920
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Diagnostic Value of Abnormal Prothrombin for Primary Liver Cancer

Hanyu Qiu
Proceedings of Anticancer Research
Hepatocellular Carcinoma Treatment and Prognosis
article

Diagnostic Value of Abnormal Prothrombin for Primary Liver Cancer

Hanyu Qiu
article en

Abstract

Objective: To investigate the diagnostic value of abnormal serum prothrombin levels in hepatocellular carcinoma (HCC). Methods: A total of 298 patients were diagnosed with HCC at Hunan Provincial People’s Hospital between January 1, 2019, and December 31, 2024, through imaging or liver biopsy, along with 100 patients with cirrhosis, 100 patients with chronic hepatitis B virus infection, and 89 healthy controls, were included in the study. Basic demographic information, as well as levels of abnormal serum prothrombin and alpha-fetoprotein (AFP), were collected. The levels of abnormal serum prothrombin and AFP across the four groups were compared, and their diagnostic efficacy for HCC was analyzed using ROC curve analysis. Results: Abnormal prothrombin levels were significantly higher in the liver cancer group compared to the cirrhosis, hepatitis, and healthy control groups (P < 0.05). No significant differences in abnormal serum prothrombin levels were observed among the cirrhosis, hepatitis, and healthy control groups (P > 0.05). Serum AFP levels were significantly higher in the liver cancer group compared to the cirrhosis, hepatitis, and healthy control groups (P < 0.05) and were higher in the hepatitis group compared to the cirrhosis and healthy control groups (P < 0.05). However, no significant difference in AFP levels was found between the cirrhosis and healthy control groups (P > 0.05). ROC curve analysis indicated that the area under the curve (AUC) for abnormal serum prothrombin and AFP in diagnosing HCC was 0.925 (95% CI: 0.901–0.949) and 0.810 (95% CI: 0.775–0.845), respectively, with sensitivities and specificities of 84% and 75% for abnormal prothrombin and 94% and 76% for AFP. For the diagnosis of AFP-negative HCC, the AUC for abnormal serum prothrombin was 0.838 (95% CI: 0.774–0.901), with a sensitivity and specificity of 65% and 95%, respectively. Conclusion: Serum abnormal prothrombin levels are highly expressed in HCC patients and demonstrate strong diagnostic efficacy for HCC.

Proceedings of Anticancer ResearchVol. 8(6)
Hunan Provincial People's Hospital (CN)
Openalex Percentile: Top 66%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.